Literature DB >> 21397197

Diagnosis and treatment of hypogonadism in men.

Shalender Bhasin1, Shehzad Basaria.   

Abstract

Androgen deficiency is diagnosed by ascertainment of characteristic signs and symptoms and consistently low testosterone levels, measured preferably in the morning using a reliable assay. The clinical presentation of androgen deficiency varies with the age of its onset, genetic factors, prior treatment, and other host factors. Androgen deficiency can be treated using any one of the approved testosterone formulations after consideration of pharmacokinetics, patient preference, cost, and potential formulation-specific adverse effects. Prostate and breast cancer, erythrocytosis, untreated severe obstructive sleep apnea, congestive heart failure, recent myocardial infarction, and severe lower urinary tract symptoms are contraindications for testosterone therapy. Testosterone therapy should be accompanied by a standardized monitoring plan that includes periodic ascertainment of symptomatic improvement and lower urinary tract symptoms, measurements of testosterone level, hematocrit, and PSA, digital prostate examination, and general health evaluation. While the benefit to risk ratio is generally favorable in healthy young men with classical hypogonadism due to diseases of the testes, pituitary and the hypothalamus, neither the clinical benefits of testosterone therapy on patient-important outcomes nor its long-term risks in older men with age-related decline in testosterone level are known.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21397197     DOI: 10.1016/j.beem.2010.12.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  23 in total

1.  Hypogonadism: Easy to define, hard to diagnose, and controversial to treat.

Authors:  Joshua Sterling; Aaron M Bernie; Ranjith Ramasamy
Journal:  Can Urol Assoc J       Date:  2015 Jan-Feb       Impact factor: 1.862

Review 2.  When and when not to use testosterone for palliation in cancer care.

Authors:  Rony Dev; Eduardo Bruera; Egidio Del Fabbro
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

Review 3.  Multiple sclerosis in men: management considerations.

Authors:  Riley Bove; Allison McHenry; Kerstin Hellwig; Maria Houtchens; Neda Razaz; Penelope Smyth; Helen Tremlett; A D Sadovnick; D Rintell
Journal:  J Neurol       Date:  2016-01-02       Impact factor: 4.849

Review 4.  Update on Testosterone Replacement Therapy in Hypogonadal Men.

Authors:  Kevin Matthew Yen Bing Leung; Khalid Alrabeeah; Serge Carrier
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

5.  Low testosterone is associated with disability in men with multiple sclerosis.

Authors:  R Bove; A Musallam; B C Healy; K Raghavan; B I Glanz; R Bakshi; H Weiner; P L De Jager; K K Miller; T Chitnis
Journal:  Mult Scler       Date:  2014-04-07       Impact factor: 6.312

Review 6.  Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men.

Authors:  C Cattabiani; S Basaria; G P Ceda; M Luci; A Vignali; F Lauretani; G Valenti; R Volpi; M Maggio
Journal:  J Endocrinol Invest       Date:  2011-11-08       Impact factor: 4.256

Review 7.  Androgen action in prostate function and disease.

Authors:  Partha P Banerjee; Subhadra Banerjee; Terry R Brown; Barry R Zirkin
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

8.  Testicular morphology in hypogonadotropic hypogonadism after the abuse of anabolic steroids.

Authors:  Armin Alibegović
Journal:  Forensic Sci Med Pathol       Date:  2018-09-03       Impact factor: 2.007

9.  Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells.

Authors:  J Y Chung; H Chen; A Midzak; A L Burnett; V Papadopoulos; B R Zirkin
Journal:  Endocrinology       Date:  2013-03-22       Impact factor: 4.736

Review 10.  Testosterone, aging and survival: biomarker or deficiency.

Authors:  Molly M Shores; Alvin M Matsumoto
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-06       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.